Stock MORF MORPHIC HOLDING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Morphic Holding, Inc.

Equities

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
27.51 USD -1.29% Intraday chart for Morphic Holding, Inc. -9.27% -4.74%
Mar. 19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT
Mar. 19 Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer CI

Business Summary

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Number of employees: 121

Managers

Managers TitleAgeSince
Praveen Tipirneni CEO
 Chief Executive Officer 55 15-06-30
Bruce Rogers PSD
 President 55 15-12-31
Marc Schegerin DFI
 Director of Finance/CFO 48 20-04-05
Blaise Lippa CTO
 Chief Tech/Sci/R&D Officer - 15-05-31
Brihad Abhyankar CTO
 Chief Tech/Sci/R&D Officer - 22-04-05
Joanne Gibbons LAW
 General Counsel - 22-05-17
William DeVaul LAW
 General Counsel 53 19-01-31
Aaron Pelta PRN
 Corporate Officer/Principal - 18-12-31
Robert Farrell AUD
 Comptroller/Controller/Auditor 58 15-05-31

Members of the board

Members of the board TitleAgeSince
Timothy Springer FOU
 Founder 76 14-07-31
Norbert W. Bischofberger BRD
 Director/Board Member 68 19-05-31
Joseph Slattery BRD
 Director/Board Member 59 19-04-30
Amir Nashat BRD
 Director/Board Member 51 17-05-31
Susannah Gray BRD
 Director/Board Member 63 21-04-26
Martin Edwards BRD
 Director/Board Member 68 20-12-03
Gustav Christensen CHM
 Chairman 76 16-03-31
Nisha Nanda BRD
 Director/Board Member 49 21-08-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,037,229 41,582,883 ( 83.10 %) 0 83.10 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
13.56 %
6,783,303 13.56 % 239 M $
Timothy Springer
9.295 %
4,650,925 9.295 % 164 M $
Point72 Asset Management LP
9.175 %
4,591,000 9.175 % 162 M $
Wellington Management Co. LLP
6.750 %
3,377,310 6.750 % 119 M $
BlackRock Advisors LLC
6.260 %
3,132,471 6.260 % 110 M $
Tas Partners LLC
5.534 %
2,768,893 5.534 % 97 M $
STATE STREET CORPORATION
5.124 %
2,564,058 5.124 % 90 M $
Vanguard Fiduciary Trust Co.
4.639 %
2,321,046 4.639 % 82 M $
T. Rowe Price International Ltd.
4.442 %
2,222,628 4.442 % 78 M $
Artal Group SA
4.273 %
2,138,188 4.273 % 75 M $

Company contact information

Morphic Holding, Inc.

35 Gatehouse Drive A2

02451, Waltham

+781 996 0955

address Morphic Holding, Inc.(MORF)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Morphic Holding, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
27.51 USD
Average target price
56.75 USD
Spread / Average Target
+106.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MORPHIC HOLDING, INC. Stock Morphic Holding, Inc.
-4.74% 1.38B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.72% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.36B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.68B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MORF Stock
  4. Company Morphic Holding, Inc.